Cormorant Asset Management’s Adicet Bio ACET Stock Holding History

Cormorant Asset Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-37,500	Closed	-$5.36M	–	73
2022 Q4	$5.36M	Sell	37,500 -50,000	-57%	-$12.5M	0.36%	54
2022 Q3	$19.9M	Sell	87,500 -25,000	-22%	-$6.35M	1.39%	27
2022 Q2	$26.3M	Buy	112,500 +65,625	+140%	+$14.4M	1.99%	19
2022 Q1	$15M	Hold	46,875	–	–	1.15%	24
2021 Q4	$13.1M	Buy	+46,875	New	+$8.04M	0.78%	36

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Cormorant Asset Management's ACET Position: Q1 2023 in Review

Cormorant Asset Management sold out of Adicet Bio (ACET) in Q1 2023, closing a stake of 37,500 shares — an estimated $5.36M sold.

Cormorant Asset Management first reported a position in ACET in Q4 2021 and held it in 5 quarters. The position peaked at $26.3M in Q2 2022. 107 funds tracked by Wall St. Rank hold ACET as of Q1 2023.

Cormorant Asset Management reported no remaining Adicet Bio position as of Q1 2023 after selling out during the quarter.
Cormorant Asset Management sold 37,500 Adicet Bio shares in Q1 2023, an estimated $5.36M.
Cormorant Asset Management first reported a position in Adicet Bio in Q4 2021 and held it in 5 quarters.
Cormorant Asset Management's Adicet Bio position peaked at $26.3M in Q2 2022.
107 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2023.

Based on Cormorant Asset Management's 13F filing for Q1 2023, filed 15 May 2023.